The study will examine the safety, tolerability and efficacy of AVR118 in patients with advanced cancer who are suffering from symptoms of progressive disease, including weight loss, fatigue and loss of appetite.
The primary objective of the study is to explore the effect of AVR118 on weight, appetite, performance status, and other measures of quality of life related to advanced malignancies as compared to patients not receiving AVR118.
The trial is being coordinated through The Biomedical Research Alliance of New York (BRANY) network of hospitals. Other participating sites include North Shore University Hospital in New York and the Medical Center of Vincennes in Indiana.
“We are pleased to add this new clinical site,” said Dr Elma Hawkins, president and CEO of Advanced Viral Research Corp. “Although it is too early to make definitive statements, patient enrollment continues to move along swiftly and we are very enthusiastic about the preliminary progress achieved in our trial.”
AVR118 has to date demonstrated a very favorable safety profile and appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papillomavirus, and to dampen aberrant autoimmune-type inflammatory responses, such as those which occur in patients with rheumatoid arthritis.